Hyppää sisältöön
    • Suomeksi
    • In English
Trepo
  • Suomeksi
  • In English
  • Kirjaudu
Näytä viite 
  •   Etusivu
  • Trepo
  • Artikkelit
  • Näytä viite
  •   Etusivu
  • Trepo
  • Artikkelit
  • Näytä viite
JavaScript is disabled for your browser. Some features of this site may not work without it.

Development and maturation of norovirus antibodies in childhood

Blazevic, Vesna; Malm, Maria; Honkanen, Hanna; Knip, Michael; Hyöty, Heikki; Vesikari, Timo (2016)

 
Avaa tiedosto
development_and_maturation_2016.pdf (533.9Kt)
Lataukset: 



Blazevic, Vesna
Malm, Maria
Honkanen, Hanna
Knip, Michael
Hyöty, Heikki
Vesikari, Timo
2016

Microbes and Infection 18 4
263-269
Lääketieteen yksikkö - School of Medicine
doi:10.1016/j.micinf.2015.12.004
Näytä kaikki kuvailutiedot
Julkaisun pysyvä osoite on
https://urn.fi/URN:NBN:fi:uta-201610062387
Tiivistelmä
The burden of norovirus (NoV) gastroenteritis is substantial in young children. Maternal antibodies are thought to protect a child from NoV infection in early infancy but subsequent development of NoV-specific protective immunity in children is still largely unexplored. We have determined NoV-specific antibody seroconversion to GII.4 virus-like particles as an indicator of NoV infection in two children prospectively followed from birth to eight years of age. Blocking activity and affinity maturation of maternal and serum IgG antibodies were evaluated. Our results show that multiple infections occur in children up to eight years of age. The titer, blocking activity and avidity of maternal antibodies determined susceptibility of an infant to NoV infection. NoV GII.4-specific antibodies with high blocking potential and avidity were developed at two to three years of age and were retained throughout the follow-up. Subsequent NoV infections may have contributed to the duration of protective NoV-specific immune responses that lasted for several years. This study adds to current understanding of the duration of passive protection by maternal antibodies and the duration and quality of acquired immunity following primary and subsequent NoV infections in infants and young children, who are the main target group for NoV vaccine development.
Kokoelmat
  • Artikkelit [6140]
Kalevantie 5
PL 617
33014 Tampereen yliopisto
oa[@]tuni.fi | Tietosuoja | Saavutettavuusseloste
 

 

Selaa kokoelmaa

TekijätNimekkeetTiedekunta (2019 -)Tiedekunta (- 2018)Tutkinto-ohjelmat ja opintosuunnatAvainsanatJulkaisuajatKokoelmat

Omat tiedot

Kirjaudu sisäänRekisteröidy
Kalevantie 5
PL 617
33014 Tampereen yliopisto
oa[@]tuni.fi | Tietosuoja | Saavutettavuusseloste